News

Hoana’s LifeBed patient vigilance system identifies patients as they begin to deteriorate and immediately notifies the hospital nursing staff – all invisible to the patient since there is

Neurogen believes that the bilayer tablet formulation of adipiplon being used in the study may not be performing as expected. The company plans additional investigation of the bilayer

Under terms of the agreement, Amgen will pay Ortho Biotech $200 million and the pending litigation in New Jersey District Court will be dismissed with prejudice. Amgen continues

The Pharos Vitesse intracranial stent is Micrus Endovascular’s second balloon-expandable stent for the treatment of intracranial ischemic stenosis and is the subject of an investigational device exemption (IDE)

The primary objective of the Phase IIa study is to assess hemodynamic effects of intravenous infusions of CD-NP in patients with heart failure. Key assessments include measurement of

The move to abandon HIV research is said to be largely in line with Roche’s strategic decision to focus only on medicines that provide a significant improvement to

The randomized, single-blind Phase I trial is designed to evaluate potential control formulations for future NGX-1998 clinical trials. NeurogesX expects to complete the trial by the end of

The Phase III study was designed to assess the efficacy and safety of long-term pegylated interferon alfa-2b versus observation. Researchers randomized patients to either peginterferon alfa-2b adjuvant treatment

This US based endometriosis clinical trial was designed to study the efficacy of Proellex in women with significant pain associated with endometriosis. The data was analyzed for subjects